Aldactone is used in suitable patients when excess aldosterone contributes to fluid retention or cardiovascular strain. Its active ingredient, spironolactone, blocks aldosterone receptors and…
Aldactone is used in suitable patients when excess aldosterone contributes to fluid retention or cardiovascular strain. Its active ingredient, spironolactone, blocks aldosterone receptors and promotes sodium and water excretion while reducing potassium loss.
Aldactone contains spironolactone, a mineralocorticoid receptor antagonist and potassium-sparing diuretic. It is a prescription treatment used when aldosterone activity contributes to fluid retention, raised blood pressure, or strain on the heart.
Spironolactone is used when aldosterone activity contributes to fluid retention, raised blood pressure, or strain on the heart. The British National Formulary and the MHRA describe spironolactone as a potassium-sparing diuretic used across several cardiovascular and fluid-balance conditions [1].
Common clinical uses include:
| Clinical setting | Main therapeutic purpose | Key monitoring point |
|---|---|---|
| Heart failure | Reduce aldosterone-related fluid retention | Potassium and kidney function |
| Hypertension | Lower blood pressure when aldosterone contributes | Blood pressure and electrolytes |
| Liver or kidney disease with oedema | Reduce sodium and water accumulation | Weight, swelling, renal function |
Spironolactone does not remove fluid instantly in every patient. The response depends on kidney function, the cause of fluid retention, sodium intake, concurrent treatment, and the prescribed dose.
Aldactone contains spironolactone, a mineralocorticoid receptor antagonist and potassium-sparing diuretic. The dose is decided individually, taking age, other medicines and health conditions into account. Spironolactone acts mainly in the distal parts of the renal tubules, where it limits the effects of aldosterone.
Aldosterone is a hormone that encourages the kidneys to retain sodium and water while removing potassium. By blocking aldosterone receptors, spironolactone promotes sodium and water excretion and reduces potassium loss. The result is lower fluid volume, less swelling, and, in suitable patients, reduced blood pressure.
Aldactone is a prescription treatment. Kidney function and serum potassium are central to treatment decisions because spironolactone can raise potassium levels.
The tablet should be swallowed as prescribed. Crushing or changing a tablet can alter how it is taken and may make dose measurement less reliable.
Spironolactone blocks mineralocorticoid receptors activated by aldosterone. These receptors influence sodium transport in the nephron, the functional unit of the kidney. Blocking them reduces sodium reabsorption and lowers the amount of water retained with sodium.
Many diuretics increase potassium loss, whereas spironolactone reduces potassium excretion. This potassium-sparing effect is useful in selected patients but can become hazardous when kidney function is poor or other potassium-raising medicines are taken at the same time.
Aldactone also has activity at other steroid hormone receptors. This explains endocrine effects such as breast tenderness, menstrual changes, reduced libido, and gynaecomastia in some patients. Eplerenone is more selective for the mineralocorticoid receptor and tends to cause fewer hormone-related effects, although it still requires potassium and renal monitoring.
The European Medicines Agency recognises mineralocorticoid receptor antagonism as a central pharmacological principle in treatment for heart failure and aldosterone-related disorders [2]. Clinical benefit is assessed through symptoms, blood pressure, swelling, body weight, kidney tests, and electrolyte results rather than by one symptom alone.
The tablet is taken by mouth. The dose is decided individually, taking age, other medicines and health conditions into account.
Prescribing decisions commonly consider:
Take Aldactone at the prescribed time each day. Taking it with food in a consistent way can help make absorption more predictable. Because it has a diuretic action, taking it late in the evening may increase night-time urination.
If a dose is missed, take it when remembered unless the next scheduled dose is near. In that situation, skip the missed dose and resume the usual schedule. Do not double the next dose.
Sudden changes to the dose can alter potassium and fluid balance. A missed dose should not be replaced with two tablets together.
Aldactone and eplerenone both block mineralocorticoid receptors. They differ in receptor selectivity and in their tendency to produce endocrine adverse effects.
| Feature | Aldactone | Eplerenone |
|---|---|---|
| Active molecule | Spironolactone | Eplerenone |
| Receptor profile | Mineralocorticoid blockade with additional steroid-receptor activity | More selective mineralocorticoid blockade |
| Common clinical distinction | Broad use with possible endocrine effects | May suit patients who develop hormone-related effects |
Clinicians may choose spironolactone when its established diuretic and aldosterone-blocking profile fits the patient’s condition. It is also familiar in heart failure, resistant hypertension, ascites, and primary hyperaldosteronism.
Eplerenone may be considered when gynaecomastia, breast tenderness, menstrual disturbance, or sexual adverse effects create a problem with spironolactone. It can still raise potassium and may be unsuitable in significant renal impairment. Selectivity does not remove the need for laboratory monitoring.
The choice depends on heart function, kidney function, potassium concentration, blood pressure, endocrine tolerability, and the rest of the treatment regimen. It is not a simple strength-for-strength substitution.
Several practical mistakes can reduce benefit or increase risk:
A daily weight record can help detect fluid changes earlier, especially in heart failure or ascites. Weighing at a similar time, using the same scales, and wearing similar clothing gives more useful information than occasional random measurements.
Aldactone is not suitable for everyone. Not for you if you have hyperkalaemia, severe kidney impairment, anuria, or an unsafe potassium-raising treatment combination. It is not appropriate when a person has:
Pregnancy requires specialist assessment because spironolactone has anti-androgenic activity and may affect fetal development. Breastfeeding also needs an individual review because treatment decisions depend on the reason for use, the dose, and the infant’s circumstances.
Aldactone may not be suitable if you have high potassium, serious kidney problems, or produce little or no urine. Extra caution is needed with diabetes, older age, dehydration, liver disease, low blood pressure, and a history of acute kidney injury. Older adults may have reduced renal reserve even when they feel well, making potassium results more important after treatment changes.
Do not use potassium supplements or potassium-based salt substitutes without checking with a clinician. Tell the prescriber about all medicines, including blood-pressure treatments, anti-inflammatory medicines, supplements, and over-the-counter products.
Regular blood tests may include serum potassium, creatinine, estimated glomerular filtration rate, and sodium. The timing depends on the indication, kidney function, and other medicines.
The most clinically significant adverse effect is hyperkalaemia, meaning an abnormally high blood potassium level. It may cause muscle weakness, unusual tiredness, tingling, palpitations, or an irregular heartbeat, although severe potassium elevation can develop with few warning symptoms.
Other possible effects include:
Gynaecomastia can appear gradually. A patient may first notice sensitivity when clothing or a seatbelt presses against the chest, rather than seeing an obvious change immediately. Menstrual changes can also develop over more than one cycle.
Seek urgent medical attention for severe weakness, collapse, confusion, marked palpitations, chest pain, severe breathlessness, or facial and throat swelling. These symptoms can signal a serious electrolyte disturbance, cardiovascular problem, or allergic reaction.
A mild increase in urination is an expected pharmacological effect rather than a sign that the treatment is damaging the kidneys. Severe thirst, very low urine output, fainting, or persistent vomiting requires prompt assessment because dehydration can worsen kidney function.
Alcohol can intensify dizziness and postural blood-pressure symptoms. It may also make it harder to recognise dehydration, especially during hot weather, vomiting, or diarrhoea.
In clinical practice, doctors usually judge spironolactone by measurable changes rather than by urine volume alone. Less ankle swelling, improved breathlessness, a steadier body weight, and better blood-pressure readings may indicate benefit. Some patients urinate only modestly more but still show meaningful improvement in fluid balance.
The first review after starting or changing treatment often focuses on potassium and kidney function. A person can feel well while potassium is rising, so symptoms cannot replace blood testing.
A common prescribing error is treating the 100 mg tablet as a universal dose. It is a tablet strength, not a dose that suits every indication. Heart failure, resistant hypertension, ascites, and hyperaldosteronism may require different schedules and follow-up plans.
Doctors also consider whether endocrine adverse effects could undermine long-term adherence. If breast tenderness or menstrual changes become troublesome, the options may include dose adjustment, a different mineralocorticoid antagonist, or a revised treatment strategy.
The WHO describes diuretic therapy as part of broader cardiovascular and fluid-management care, with treatment selected according to the patient’s disease and risk factors [3]. Spironolactone works best when fluid status, renal function, potassium, and the underlying condition are assessed together.
Aldactone is ruled out in people with hyperkalaemia, anuria, or severe renal impairment unless a specialist has established a different plan. The risk comes from reduced potassium excretion and impaired kidney clearance. The MHRA safety information and British prescribing references emphasise renal function and potassium assessment before and during treatment, with guidance current to clinical practice in 2026 [4]. A person with Addison’s disease also needs specialist assessment before spironolactone is considered.
Alcohol can increase dizziness, light-headedness, and dehydration while taking spironolactone. The effect may be stronger in people using other blood-pressure medicines, recovering from illness, or losing fluid through vomiting or diarrhoea. NHS prescribing advice and cardiovascular practice guidance continue to treat dehydration and postural symptoms as relevant concerns in 2026. Avoiding heavy alcohol intake is sensible when the response to treatment is not yet established.
Persistent swelling, high blood pressure, or breathlessness needs clinical review rather than an extra tablet. The cause may be insufficient response, poor absorption, worsening heart or kidney disease, excess sodium intake, or an interacting medicine. The EMA’s information on mineralocorticoid receptor antagonists supports reassessing renal function, potassium, fluid status, and the wider treatment plan when the response is inadequate [5]. Do not increase Aldactone independently.
Older adults can use spironolactone when the indication, kidney function, potassium level, and other medicines have been assessed. Age-related reduction in renal reserve increases the risk of hyperkalaemia and acute kidney injury. Geriatric prescribing practice in 2026 places emphasis on lower-risk dosing decisions, blood-test follow-up, hydration status, and review of non-prescription medicines. Dizziness and falls also deserve attention if blood pressure falls.
Pregnancy requires specialist evaluation because spironolactone has anti-androgenic effects and may pose a risk to fetal development. Breastfeeding decisions depend on the treatment indication, dose, maternal kidney function, and the infant’s health. The MHRA and EMA medicine-safety frameworks treat pregnancy and lactation as circumstances requiring an individual benefit–risk assessment in 2026. Do not start, stop, or substitute treatment during pregnancy without a documented clinical plan.
Stopping spironolactone can allow fluid retention, raised blood pressure, or the underlying aldosterone-related problem to return. Whether tapering is needed depends on the indication, duration of treatment, dose, heart and kidney function, and the other medicines being used. Cardiovascular guidance used by the WHO and UK clinicians supports planned treatment changes when fluid balance or heart failure is involved. Stopping suddenly without a plan can make it harder to distinguish disease progression from a medication change.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Based on 5 reviews
I used Aldactone for fluid retention linked to my treatment. The ankle swelling eased during the second week, and I noticed I was visiting the toilet more often in the morning. I had mild dizziness when standing quickly, so the timing and blood-pressure checks mattered.
Stoke-on-Trent Six weeks 30 Sept 2026The tablets reduced the bloated feeling I had been dealing with. I made the mistake of taking one just before bed and slept badly because of the urination. Moving it earlier helped, although I still needed follow-up blood tests.
Liverpool One month 9 Oct 2026My blood pressure readings improved after the treatment was added. I did not notice much at first, which was frustrating. The drawback was breast tenderness, and my prescriber later reviewed whether another option would suit me better.
Cardiff Three months 12 Oct 2026The swelling around my ankles became less noticeable and my weight was steadier. I felt tired on some afternoons, although it was difficult to tell whether that came from Aldactone or my heart condition. The potassium test results were reassuring during follow-up.
Milton Keynes Eight weeks 23 Oct 2026I stopped taking it after the swelling improved, then the problem returned. Restarting without advice was not sensible because I was also taking another medicine that could affect potassium. The review clarified the schedule and the need for monitoring.
Portsmouth Four weeks 28 Oct 2026
